-
11.发明授权公开(公告)号：US07737137B2
公开(公告)日：2010-06-15
申请号：US12197760
申请日：2008-08-25
申请人： Michael E. Brune , Peer B. Jacobson , Jeffrey J. Rohde , Jiahong Wang , Steven Fung , Ravi Kurukulasuriya , David J. Madar , James T. Link , Vince S. Yeh
发明人： Michael E. Brune , Peer B. Jacobson , Jeffrey J. Rohde , Jiahong Wang , Steven Fung , Ravi Kurukulasuriya , David J. Madar , James T. Link , Vince S. Yeh
CPC分类号： C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
摘要： Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 用于治疗患有糖皮质激素相关疾病和病症的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂，其中所述抑制剂是式（I）的化合物： 或其药学上可接受的盐，前药，前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗由过度糖皮质激素作用介导的神经元变性，功能障碍，急性精神病，焦虑，痴呆，抑郁症，非胰岛素依赖型2型糖尿病，胰岛素抵抗，肥胖症，脂质疾病，代谢综合征和其他疾病和病症的方法。
-
12.发明授权公开(公告)号：US07855308B2
公开(公告)日：2010-12-21
申请号：US12355909
申请日：2009-01-19
申请人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
发明人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
IPC分类号： C07C233/05 , A61K31/65
CPC分类号： C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
13.发明申请公开(公告)号：US20090131434A1
公开(公告)日：2009-05-21
申请号：US12355909
申请日：2009-01-19
申请人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
发明人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
IPC分类号： A61K31/5377 , C07C233/01 , C07D413/02 , A61P3/10 , A61K31/16
CPC分类号： C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
14.发明申请公开(公告)号：US20080312214A1
公开(公告)日：2008-12-18
申请号：US12197760
申请日：2008-08-25
IPC分类号： A61K31/55 , A61K31/4439 , A61K31/4015 , A61P25/22 , A61P25/24 , A61P25/28
CPC分类号： C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
摘要： Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 用于治疗患有糖皮质激素相关疾病和病症的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂，其中所述抑制剂是式（I）的化合物： 或其药学上可接受的盐，前药，前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗由过度糖皮质激素作用介导的神经元变性，功能障碍，急性精神病，焦虑，痴呆，抑郁症，非胰岛素依赖型2型糖尿病，胰岛素抵抗，肥胖症，脂质疾病，代谢综合征和其他疾病和病症的方法。
-
15.发明授权公开(公告)号：US07435833B2
公开(公告)日：2008-10-14
申请号：US11697044
申请日：2007-04-05
IPC分类号： C07D207/00 , C07D403/00 , A61K31/00
CPC分类号： C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
摘要： A compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 式（I）的化合物或其药学上可接受的盐，前药，前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗非胰岛素依赖型2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征等由过度糖皮质激素作用介导的疾病和病症的方法。
-
公开(公告)号：US08202878B2
公开(公告)日：2012-06-19
申请号：US11947005
申请日：2007-11-29
申请人： Andrew J. Souers , Ju Gao , Todd M. Hansen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
发明人： Andrew J. Souers , Ju Gao , Todd M. Hansen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
IPC分类号： C07D487/04 , A61K31/519 , A61P3/04 , A61P3/10 , C07D231/20 , A61K31/4152
CPC分类号： C07D487/04 , C07C59/54 , C07C275/42 , C07D211/60 , C07D231/12 , C07D231/20 , C07D249/08 , C07D263/48 , C07D277/40 , C07D401/04 , C07D407/12 , C07D407/14 , C07D413/12 , C07D413/14
摘要： The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of formula (I), and related methods for treating or preventing metabolic diseases or conditions.
摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，式（I）的药物组合物以及用于治疗或预防代谢性疾病或病症的相关方法。
-
公开(公告)号：US20120238581A1
公开(公告)日：2012-09-20
申请号：US13484539
申请日：2012-05-31
申请人： Andrew J. Souers , Ju Gao , Todd M. Hasen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
发明人： Andrew J. Souers , Ju Gao , Todd M. Hasen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
IPC分类号： A61K31/415 , C07D405/14 , A61K31/4155 , C07D405/12 , C07D413/12 , A61K31/422 , C07D249/08 , A61K31/4196 , C07D413/14 , C07D403/12 , C07D277/42 , A61K31/426 , C07D401/12 , A61K31/4439 , C07D241/12 , A61K31/4965 , C07D487/04 , A61K31/519 , A61P3/10 , A61P3/04 , A61P3/06 , A61P3/00 , A61P1/16 , A61K31/454 , A61K31/455 , C07D231/20
CPC分类号： C07D487/04 , C07C59/54 , C07C275/42 , C07D211/60 , C07D231/12 , C07D231/20 , C07D249/08 , C07D263/48 , C07D277/40 , C07D401/04 , C07D407/12 , C07D407/14 , C07D413/12 , C07D413/14
摘要： Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.
摘要翻译： 式（I）化合物或其药学上可接受的盐，前药，前药的盐或其组合。 式（I）的药物组合物和治疗或预防代谢疾病或病症的相关方法。
-
公开(公告)号：US08586594B2
公开(公告)日：2013-11-19
申请号：US13484539
申请日：2012-05-31
申请人： Andrew J. Souers , Ju Gao , Todd M. Hansen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
发明人： Andrew J. Souers , Ju Gao , Todd M. Hansen , Rajesh R. Iyengar , Philip R. Kym , Bo Liu , Zhonghua Pei , Vince S. Yeh , Gang Zhao , Zhili Xin
IPC分类号： A61K31/519 , A61P3/04 , A61P3/10 , A61K31/4152 , C07D487/04 , C07D231/20
CPC分类号： C07D487/04 , C07C59/54 , C07C275/42 , C07D211/60 , C07D231/12 , C07D231/20 , C07D249/08 , C07D263/48 , C07D277/40 , C07D401/04 , C07D407/12 , C07D407/14 , C07D413/12 , C07D413/14
摘要： Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.
摘要翻译： 式（I）化合物或其药学上可接受的盐，前药，前药的盐或其组合。 式（I）的药物组合物和治疗或预防代谢疾病或病症的相关方法。
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.079 秒)
